Cargando…

Autologous Fat Grafting in the Treatment of Facial Scleroderma

Systemic sclerosis (SSc) is a rare systemic autoimmune disease, characterized by progressive cutaneous and internal organ fibrosis. Orofacial manifestations of systemic sclerosis are extremely disabling and treatment options are limited. In this study, we aimed to assess the safety and efficacy of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gheisari, Mehdi, Ahmadzadeh, Arman, Nobari, Nilofar, Iranmanesh, Behzad, Mozafari, Nikoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093005/
https://www.ncbi.nlm.nih.gov/pubmed/30154838
http://dx.doi.org/10.1155/2018/6568016
_version_ 1783347629376143360
author Gheisari, Mehdi
Ahmadzadeh, Arman
Nobari, Nilofar
Iranmanesh, Behzad
Mozafari, Nikoo
author_facet Gheisari, Mehdi
Ahmadzadeh, Arman
Nobari, Nilofar
Iranmanesh, Behzad
Mozafari, Nikoo
author_sort Gheisari, Mehdi
collection PubMed
description Systemic sclerosis (SSc) is a rare systemic autoimmune disease, characterized by progressive cutaneous and internal organ fibrosis. Orofacial manifestations of systemic sclerosis are extremely disabling and treatment options are limited. In this study, we aimed to assess the safety and efficacy of autologous fat grafting in the face of patients with systemic sclerosis. We enrolled 16 SSc patients suffering from facial sclerosis and limited mouth opening capacity. Autologous fat injection ranging from 15 to 40 ml was administered per patient, based on their face morphology. The patients were evaluated at baseline and 3 months after fat injection. Evaluations included mouth opening capacity, mouth handicap in systemic sclerosis (MHISS), Rodnan skin sclerosis score, skin biophysical properties using a sensitive biometrologic device with the assessment of cutaneous resonance running time (CRRT), volumizing and aesthetic effects based on pre- and posttreatment photographs, possible side effects, and global patient satisfaction. Clinical assessment showed autologous fat transfer significantly improved mouth opening capacity and the MHISS and Rodnan score of patients with facial scleroderma (p value <.001). The aesthetic and/or functional results of fat injection were satisfying to about 80% of the patients. The changes in CRRT values were not significant. Our findings support the possible therapeutic role of autologous fat grafting in improving facial scleroderma both in aesthetic and in functional aspects. This trial is registered with IRCT20180209038677N1.
format Online
Article
Text
id pubmed-6093005
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-60930052018-08-28 Autologous Fat Grafting in the Treatment of Facial Scleroderma Gheisari, Mehdi Ahmadzadeh, Arman Nobari, Nilofar Iranmanesh, Behzad Mozafari, Nikoo Dermatol Res Pract Clinical Study Systemic sclerosis (SSc) is a rare systemic autoimmune disease, characterized by progressive cutaneous and internal organ fibrosis. Orofacial manifestations of systemic sclerosis are extremely disabling and treatment options are limited. In this study, we aimed to assess the safety and efficacy of autologous fat grafting in the face of patients with systemic sclerosis. We enrolled 16 SSc patients suffering from facial sclerosis and limited mouth opening capacity. Autologous fat injection ranging from 15 to 40 ml was administered per patient, based on their face morphology. The patients were evaluated at baseline and 3 months after fat injection. Evaluations included mouth opening capacity, mouth handicap in systemic sclerosis (MHISS), Rodnan skin sclerosis score, skin biophysical properties using a sensitive biometrologic device with the assessment of cutaneous resonance running time (CRRT), volumizing and aesthetic effects based on pre- and posttreatment photographs, possible side effects, and global patient satisfaction. Clinical assessment showed autologous fat transfer significantly improved mouth opening capacity and the MHISS and Rodnan score of patients with facial scleroderma (p value <.001). The aesthetic and/or functional results of fat injection were satisfying to about 80% of the patients. The changes in CRRT values were not significant. Our findings support the possible therapeutic role of autologous fat grafting in improving facial scleroderma both in aesthetic and in functional aspects. This trial is registered with IRCT20180209038677N1. Hindawi 2018-08-01 /pmc/articles/PMC6093005/ /pubmed/30154838 http://dx.doi.org/10.1155/2018/6568016 Text en Copyright © 2018 Mehdi Gheisari et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Gheisari, Mehdi
Ahmadzadeh, Arman
Nobari, Nilofar
Iranmanesh, Behzad
Mozafari, Nikoo
Autologous Fat Grafting in the Treatment of Facial Scleroderma
title Autologous Fat Grafting in the Treatment of Facial Scleroderma
title_full Autologous Fat Grafting in the Treatment of Facial Scleroderma
title_fullStr Autologous Fat Grafting in the Treatment of Facial Scleroderma
title_full_unstemmed Autologous Fat Grafting in the Treatment of Facial Scleroderma
title_short Autologous Fat Grafting in the Treatment of Facial Scleroderma
title_sort autologous fat grafting in the treatment of facial scleroderma
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093005/
https://www.ncbi.nlm.nih.gov/pubmed/30154838
http://dx.doi.org/10.1155/2018/6568016
work_keys_str_mv AT gheisarimehdi autologousfatgraftinginthetreatmentoffacialscleroderma
AT ahmadzadeharman autologousfatgraftinginthetreatmentoffacialscleroderma
AT nobarinilofar autologousfatgraftinginthetreatmentoffacialscleroderma
AT iranmaneshbehzad autologousfatgraftinginthetreatmentoffacialscleroderma
AT mozafarinikoo autologousfatgraftinginthetreatmentoffacialscleroderma